| Decitabine in chronic leukemias. | |
| | |
MedLine Citation:
|
PMID: 16015505 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
5-Aza-2'-deoxycitidine (decitabine, Dacogen, Bloomington, MN) is a cytosine analogue that promotes hypomethylation of DNA and has documented efficacy in myeloid malignancies. Indeed, promising clinical results have been observed in acute myeloid leukemia (AML) and the myelodysplastic syndromes (MDS). Aberrant methylation has also been found in chronic leukemias, providing a rationale for investigating the use of decitabine in these diseases. There is clear evidence of molecular (hypomethylation) as well as hematologic and cytogenetic responses to decitabine in chronic myelogenous leukemia of all phases, including in patients resistant to imatinib mesylate. Clinical trials of decitabine in chronic lymphocytic leukemia are ongoing. There are many unanswered questions regarding optimizing this treatment for chronic leukemias, but successful proof-of-concept studies for hypomethylating agents move us closer to approaches that may have a significant impact on patient outcomes. |
| | |
Authors:
|
Jean-Pierre J Issa; John C Byrd |
Related Documents
:
|
15898935 - Characteristics of periodontal microflora in acute myocardial infarction. 22132535 - Eating your words: getting the right messages across. 9816215 - Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implic... 7660765 - Acute pancreatitis in pregnancy. 18164305 - Zygote score and status 1 or 2 days after cleavage and assisted reproduction outcome. 10819865 - Effect of external cephalic version at term on fetal circulation. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; Review |
Journal Detail:
|
Title: Seminars in hematology Volume: 42 ISSN: 0037-1963 ISO Abbreviation: Semin. Hematol. Publication Date: 2005 Jul |
Date Detail:
|
Created Date: 2005-07-14 Completed Date: 2005-10-06 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0404514 Medline TA: Semin Hematol Country: United States |
Other Details:
|
Languages: eng Pagination: S43-9 Citation Subset: IM |
Affiliation:
|
Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA. jpissa@mdanderson.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Azacitidine
/
administration & dosage,
analogs & derivatives*,
therapeutic use Chronic Disease Combined Modality Therapy Hematopoietic Stem Cell Transplantation Humans Leukemia / drug therapy* Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy |
| Chemical | |
Reg. No./Substance:
|
2353-33-5/decitabine; 320-67-2/Azacitidine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Decitabine in acute myeloid leukemia.
Next Document: Future directions for the use of hypomethylating agents.